FDA Approves New Dosage of HIV Medication Prestiza


Recently approved dosage of Prestiza (darunavir) tablets will allow patients to take fewer pills each day.

According to a news release from Janssen Therapeutics, Division of Janssen Products, LP, the FDA recently approved an 800mg tablet dosage of Prestiza (darunavir), which is indicated for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations.

Prestiza (darunavir) should always be taken with and at the same time as ritonavir with food and in combination with other HIV medicines.

According to Janssen, the new tablet strength will allow patients taking Prestiza once daily “to reduce the number of Prestiza tablets by half, taking one 800mg tablet instead of two 400mg tablets once a day with ritonavir 100mg and other antiretroviral medications.”

The company reported that the 800mg tablet “is expected to be available shortly.” The company also announced that it plans to discontinue the Prestiza 400mg tablet, “which will become obsolete as a result of the introduction of the 800mg tablet.”

Related Videos
Video 3 - "HIV Treatment: Discussing Adverse Events with Patients"
Video 3 - "Key Clinical Considerations in HIV Treatment Decisions"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
© 2024 MJH Life Sciences

All rights reserved.